April 27, 2021 News by Marisa Wexler, MS #AANAM – Early Ocrevus Treatment Helps to Protect Nervous System Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Treating multiple sclerosis (MS) in its earlier stages with Ocrevus (ocrelizumab) can substantially lower disease activity and lessen damage…
January 28, 2021 News by Marisa Wexler, MS NfL Mirrors Some Life Quality Aspects Felt by Patients, More Work Needed Levels of neurofilament light (NfL), a protein marker of neuronal damage, appear to capture some aspects of patient‐perceived physical and functional abilities with multiple sclerosis (MS), as well as their utilization of select healthcare services, a real-world study suggests. Its researchers, however, stress that more work is needed before NfL levels…
November 12, 2020 News by Marisa Wexler, MS Neurofilament Light Levels at First MS Event Can Predict Long-term Brain Atrophy The levels of the protein neurofilament light chain (NfL) in the blood when a person experiences a first demyelinating event associated with multiple sclerosis (MS) can predict brain atrophy up to a decade later, a new study shows. Titled “Association of Serum Neurofilament Light Levels…
April 23, 2018 News by Alice Melão, MSc #AAN2018 – Neurofilament Light Blood Levels Can Help Define Disease Activity in RRMS, Study Shows Analysis of a potential blood biomarker linked to brain cell damage can help define disease activity in patients with relapsing-remitting multiple sclerosis (RRMS). Results of a study showed that determining blood levels of neurofilament light chain, or NfL, could help in establishing “no evidence of disease activity,” or NEDA, status…
April 19, 2018 News by Patricia Inacio, PhD #AAN2018 – Biogen Data Covers Work into an MS Blood Biomarker, Cognition and Life Quality Research that points to a potential blood biomarker of multiple sclerosis (MS) severity, relates cognitive difficulties to patients’ employment and other measures of socioeconomic status, and one-year results of an ongoing clinical trial are among data presentations planned by Biogen for the annual meeting of the American Academy of Neurology (AAN). This year’s…
December 13, 2017 News by Patricia Silva, PhD Levels of Nerve Protein in Blood Provide Good Grasp of MS Activity, Study Finds Blood levels of the nerve damage marker neurofilament light provide a reliable picture of multiple sclerosis activity in both the relapsing-remitting and progressive forms of the disease, a Swedish study reports. The University of Gothenburg researchers also discovered a close link between its levels in blood and spinal fluid. This means the…
November 17, 2016 News by Patricia Silva, PhD Assay Able to Detect Neuron Damage in Blood May Serve as Early MS Diagnostic Tool Quanterix and UmanDiagnostics are working to advance an assay capable of detecting neuron damage in a blood sample — a tool that could aid in the early diagnosis of multiple sclerosis (MS) and other neurodegenerative conditions. The collaboration brings Quanterix’ Simoa technology together with Uman’s antibodies against neurofilament light (Nf-L) — a…
